Dean Fergusson profile picture

Contact Information

Dean Fergusson, PhD, MHA

Administrative Coordinator:
Jodi Peters
613-737-8899 x79842

ORCID logo

Dean Fergusson

Senior Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Director, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Full Professor, Departments of Medicine, Surgery, & the School of Epidemiology and Public Health
University of Ottawa
Endowed Chair, Clinical Epidemiology Program
Ottawa Hospital Research Institute/University of Ottawa
Scientific Co-Lead, Ontario SPOR SUPPORT Unit
Government of Ontario and the Canadian Institutes of Health Research
Society for Clinical Trials

Research Interests

I have focused my research contributions in two major areas:
1) transfusions and transfusion alternatives
2) methodological research into the ethics, design and analysis of clinical trials.

Brief Biography

Dr. Fergusson is a Senior Scientist & Director, Clinical Epidemiology Program, at the Ottawa Hospital Research Institute. He is also a Full Professor, Departments of Medicine, Surgery, & of the School of Epidemiology and Public Health, University of Ottawa. Dr. Fergusson holds the position of Endowed Chair, OHRI/uOttawa, Clinical Epidemiology Program.

He holds a PhD (Honours) in Epidemiology and Biostatistics from McGill University and a Masters of Health Administration from the University of Ottawa. Dr. Fergusson’s clinical research interests are mainly in the field of transfusion medicine with a focus on transfusion alternatives and the effectiveness of blood products. His research interests also extend to the methodology and ethics of clinical trials and systematic reviews. Dr. Fergusson is also the co-lead of the Rethinking Clinical Trials (REaCT) Program which performs practical patient-focused research that ensures that patients receive optimal, safe, cost effective treatment. It includes the pragmatic evaluation of standard, usual care interventions using efficient informed consent, efficient routinely collected electronic administrative and clinical data, and immediate implementation of findings into routine TOH practice. Dr. Fergusson is a principal investigator on a number of large, peer-reviewed clinical trials in transfusion medicine including “Blood Conservation Using Antifibrinolytics: Randomized Trial in High-Risk Cardiac Surgery (BART)”, Age of Red Blood Cells in Premature Infants (ARIPI), “Age of Blood Evaluation (ABLE)”. Dr. Fergusson has contributed over 450 articles, abstracts, and book chapters to the medical literature.

Selected Publications

  1. Fergusson D, Monfaredi Z, Pussegoda K, Garritty C, Lyddiatt A, Shea B, Duffett L, Ghannad M, Montroy J, Hassan Murad M, Pratt M, Rader T, Shorr R, Yazdi F. The prevalence of patient engagement in published trials: a systematic review. Res Involv Engagem. 2018 May 22;4:17. 
  2. Mazer CD, Whitlock RP, Fergusson DA, Hall J, Belley-Cote E, Connolly K, Khanykin B, Gregory AJ, de Médicis É, McGuinness S, Royse A, Carrier FM, Young PJ, Villar JC, Grocott HP, Seeberger MD, Fremes S, Lellouche F, Syed S, Byrne K, Bagshaw SM, Hwang NC, Mehta C, Painter TW, Royse C, Verma S, Hare GMT, Cohen A, Thorpe KE, Jüni P, Shehata N; TRICS Investigators and Perioperative Anesthesia Clinical Trials Group. Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery. N Engl J Med. 2017 Nov 30;377(22):2133-2144.
  3. Lacroix J, Hébert PC, Fergusson DA, Tinmouth A, Cook DJ, Marshall JC, Clayton L, McIntyre L, Callum J, Turgeon AF, Blajchman MA, Walsh TS, Stanworth SJ, Campbell H, Capellier G, Tiberghien P, Bardiaux L, van de Watering L, van der Meer NJ, Sabri E, Vo D; ABLE Investigators and the Canadian Critical Care Trials Group.(2015). Age of Transfused Blood in Critically Ill Adults. N Engl J Med.372(15):1410-8
  4. Zarychanski R , Abou-Setta AM , Turgeon AF , Houston BL , McIntyre L , Marshall JC , Fergusson DA. (2013). Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA. 309(7): 678-88.
  5. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R; BART Investigators.(2008). A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. The New England journal of medicine. 358(22): 2319-31.

Diseases, conditions and populations of interest

Research and clinical approaches